Phase 1 subcutaneous blinatumomab safe, effective in R/R B-ALL

Elias Jabbour, MD, leukemia professor in the University of Texas MD Anderson Cancer Center, discusses the phase 1/2 expansion study of subcutaneous blinatumomab being investigated in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Data from the trail were presented during the 2025 EHA Congress in Milan.